Legend Biotech Financials
LEGN Stock | USD 40.94 1.19 2.99% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Debt Equity Ratio | 0.31 | 0.2248 |
|
| |||||
Current Ratio | 7.27 | 6.9209 |
|
|
The financial analysis of Legend Biotech is a critical element in measuring its lifeblood. Investors should not minimize Legend Biotech's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
Legend | Select Account or Indicator |
Understanding current and past Legend Biotech Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Legend Biotech's financial statements are interrelated, with each one affecting the others. For example, an increase in Legend Biotech's assets may result in an increase in income on the income statement.
Legend Biotech Stock Summary
Legend Biotech competes with Eliem Therapeutics, HCW Biologics, Scpharmaceuticals, Milestone Pharmaceuticals, and Seres Therapeutics. Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation. Legend Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1071 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US52490G1022 |
CUSIP | 52490G102 |
Location | New Jersey; U.S.A |
Business Address | 2101 Cottontail Lane, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.legendbiotech.com |
Phone | 732 317 5050 |
Currency | USD - US Dollar |
Legend Biotech Key Financial Ratios
Return On Equity | -0.28 | ||||
Profit Margin | (0.67) % | ||||
Operating Margin | (0.44) % | ||||
Price To Sales | 14.44 X | ||||
Revenue | 285.14 M |
Legend Biotech Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 287.7M | 721.0M | 1.1B | 1.3B | 1.8B | 938.8M | |
Other Current Liab | 70.9M | 100.1M | 220.7M | 248.0M | 185.9M | 150.0M | |
Other Liab | 277.8M | 277.7M | 244.8M | 7.9M | 7.1M | 6.7M | |
Net Tangible Assets | (123.4M) | 277.4M | 466.5M | 740.9M | 852.0M | 894.6M | |
Net Debt | (77.3M) | (452.3M) | (566.0M) | (501.5M) | (949.0M) | (901.6M) | |
Retained Earnings | (127.3M) | (430.8M) | (817.0M) | (966.5M) | (1.5B) | (1.4B) | |
Accounts Payable | 9.6M | 4.9M | 7.0M | 32.9M | 20.2M | 13.6M | |
Cash | 83.4M | 455.7M | 688.9M | 786.0M | 1.3B | 1.3B | |
Other Assets | 70.2M | 665K | 4.2M | 7.3M | 67.7M | 0.95 | |
Net Receivables | 35.8M | 75.6M | 50.5M | 45.5M | 157.1M | 80.2M | |
Inventory | 1.2M | 1.8M | 1.7M | 10.4M | 19.4M | 20.4M | |
Other Current Assets | 11.3M | 10.8M | 15.2M | 62.8M | 12.6M | 17.9M | |
Total Liab | 410.6M | 440.8M | 647.2M | 586.7M | 597.2M | 523.2M | |
Total Current Assets | 207.1M | 592.9M | 948.8M | 1.1B | 1.5B | 770.5M | |
Short Term Debt | 1.0M | 1.5M | 911K | 7.1M | 3.2M | 2.2M | |
Intangible Assets | 5.1M | 7.7M | 4.7M | 3.4M | 4.1M | 3.9M | |
Net Invested Capital | (122.9M) | 280.3M | 591.7M | 1.0B | 1.5B | 1.6B | |
Net Working Capital | 79.3M | 431.7M | 668.5M | 801.3M | 1.3B | 1.3B |
Legend Biotech Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Tax Provision | 2.6M | (4.1M) | 1K | 625K | 283K | 268.9K | |
Interest Expense | 223K | 4.2M | 900K | 10.8M | 21.8M | 22.9M | |
Total Revenue | 57.3M | 75.7M | 89.8M | 117.0M | 285.1M | 299.4M | |
Gross Profit | 57.3M | (156.5M) | (223.6M) | 51.6M | 140.9M | 148.0M | |
Operating Income | (130.9M) | (313.3M) | (393.0M) | (455.8M) | (439.5M) | (417.5M) | |
Ebit | (130.9M) | (304.1M) | (406.3M) | (434.9M) | (498.3M) | (473.4M) | |
Research Development | 161.9M | 232.2M | 313.3M | 335.6M | 382.2M | 234.8M | |
Ebitda | (125.6M) | (294.1M) | (392.4M) | (416.5M) | (477.9M) | (454.0M) | |
Income Before Tax | (130.4M) | (307.6M) | (386.2M) | (445.7M) | (520.1M) | (494.1M) | |
Net Income | (133.0M) | (303.5M) | (386.2M) | (446.3M) | (518.3M) | (492.3M) | |
Income Tax Expense | 2.6M | (4.1M) | 1K | 625K | (1.9M) | (1.8M) | |
Net Interest Income | 4.4M | (4.2M) | (900K) | (10.8M) | 21.2M | 22.3M | |
Interest Income | 4.6M | 2.9M | 971K | 8.2M | 42.1M | 44.2M |
Legend Biotech Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change To Inventory | (22K) | (643K) | 51K | (8.6M) | (12.7M) | (12.1M) | |
Investments | (58.7M) | 25.6M | (195.0M) | (78.3M) | 92.8M | 97.4M | |
Change In Cash | (126.8M) | 372.3M | 233.2M | 97.1M | 490.8M | 515.3M | |
Net Borrowings | 14.7M | (2.6M) | (1.4M) | (2.6M) | (2.3M) | (2.2M) | |
Free Cash Flow | (122.2M) | (272.8M) | (245.6M) | (222.3M) | (416.0M) | (395.2M) | |
Depreciation | 5.3M | 9.9M | 13.9M | 18.4M | 20.5M | 11.0M | |
Other Non Cash Items | (4.4M) | 84.6M | 187.7M | 6.6M | 128.2M | 71.5M | |
Capital Expenditures | 39.2M | 49.8M | 47.1M | 22.3M | 22.7M | 31.9M | |
Net Income | (130.4M) | (307.6M) | (386.2M) | (445.7M) | (518.3M) | (492.3M) | |
End Period Cash Flow | 83.4M | 455.7M | 688.9M | 786.0M | 1.3B | 1.3B | |
Change To Netincome | (7.8M) | 92.0M | 187.7M | 34.2M | 39.3M | 55.1M |
Legend Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Legend Biotech's current stock value. Our valuation model uses many indicators to compare Legend Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Legend Biotech competition to find correlations between indicators driving Legend Biotech's intrinsic value. More Info.Legend Biotech Corp is currently regarded as number one stock in return on equity category among its peers. It is rated second overall in return on asset category among its peers . At this time, Legend Biotech's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Legend Biotech's earnings, one of the primary drivers of an investment's value.Legend Biotech Corp Systematic Risk
Legend Biotech's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Legend Biotech volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Legend Biotech Corp correlated with the market. If Beta is less than 0 Legend Biotech generally moves in the opposite direction as compared to the market. If Legend Biotech Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Legend Biotech Corp is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Legend Biotech is generally in the same direction as the market. If Beta > 1 Legend Biotech moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Legend Biotech Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Legend Biotech's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Legend Biotech growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Legend Biotech November 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Legend Biotech help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Legend Biotech Corp. We use our internally-developed statistical techniques to arrive at the intrinsic value of Legend Biotech Corp based on widely used predictive technical indicators. In general, we focus on analyzing Legend Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Legend Biotech's daily price indicators and compare them against related drivers.
Information Ratio | (0.19) | |||
Maximum Drawdown | 17.18 | |||
Value At Risk | (5.82) | |||
Potential Upside | 4.29 |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Legend Biotech Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Legend Biotech. If investors know Legend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Legend Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.92) | Revenue Per Share 2.851 | Quarterly Revenue Growth 0.669 | Return On Assets (0.12) | Return On Equity (0.28) |
The market value of Legend Biotech Corp is measured differently than its book value, which is the value of Legend that is recorded on the company's balance sheet. Investors also form their own opinion of Legend Biotech's value that differs from its market value or its book value, called intrinsic value, which is Legend Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Legend Biotech's market value can be influenced by many factors that don't directly affect Legend Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Legend Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Legend Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Legend Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.